Empagliflozin-pirfenidone dual therapy improves cardiac function and structure in a preclinical two-hit HFpEF model.

Yu Y, Xu Y, Chen J, Yao Y, Liu Y, Huang T, Yang S, Ling KH, Guyette JP, Shaharuddin B, Guo Z, Tan JJ.

Open source

DOI: 10.3389/fphar.2026.1781866
Published: 2026-06-03
Container: Front Pharmacol
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1781866,
  title = {Empagliflozin-pirfenidone dual therapy improves cardiac function and structure in a preclinical two-hit HFpEF model.},
  author = {Yu Y and  Xu Y and  Chen J and  Yao Y and  Liu Y and  Huang T and  Yang S and  Ling KH and  Guyette JP and  Shaharuddin B and  Guo Z and  Tan JJ.},
  year = {2026},
  journal = {Front Pharmacol},
  doi = {10.3389/fphar.2026.1781866},
  url = {https://doi.org/10.3389/fphar.2026.1781866}
}

RIS

TY  - JOUR
TI  - Empagliflozin-pirfenidone dual therapy improves cardiac function and structure in a preclinical two-hit HFpEF model.
AU  - Yu Y
AU  -  Xu Y
AU  -  Chen J
AU  -  Yao Y
AU  -  Liu Y
AU  -  Huang T
AU  -  Yang S
AU  -  Ling KH
AU  -  Guyette JP
AU  -  Shaharuddin B
AU  -  Guo Z
AU  -  Tan JJ.
PY  - 2026
JO  - Front Pharmacol
DO  - 10.3389/fphar.2026.1781866
UR  - https://doi.org/10.3389/fphar.2026.1781866
ER  -

APA

Y, Y., Y, X., J, C., Y, Y., Y, L., T, H., S, Y., KH, L., JP, G., B, S., Z, G., & JJ., T. (2026). Empagliflozin-pirfenidone dual therapy improves cardiac function and structure in a preclinical two-hit HFpEF model.. Front Pharmacol. https://doi.org/10.3389/fphar.2026.1781866

Source records

europe-pmc · retrieved 2026-09-27T09:26:49.823Z
doaj · retrieved 2026-09-27T09:26:49.759Z